go-v.orgdoi

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro

Andra Tilgase, Liene Patetko, Ilze Blāķe, Anna Ramata‐Stunda, Mārtiņs Borodušķis, Pēteris Alberts · Journal of Cancer · 2018

  • DOI 10.7150/jca.23242
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2018

Abstract

Background: The role of oncolytic viruses in cancer treatment is increasingly studied.The first oncolytic virus (Rigvir®, ECHO-7) was registered in Latvia over a decade ago.In a recent retrospective study Rigvir® decreased mortality 4.39-6.57-fold in stage IB-IIC melanoma patients.The aims of the present study are to test the effect of Rigvir® on cell line viability in vitro and to visualize the cellular presence of Rigvir® by immunocytochemistry.Methods: The cytolytic effect of Rigvir® on the viability of FM-9, RD, AGS, A549, HDFa, HPAF-II, MSC, MCF7, HaCaT, and Sk-Mel-28 cell lines was measured using live cell imaging.PBMC viability was measured using flow cytometry.The presence of ECHO-7 virus was visualized using immunocytochemistry.Statistical difference between treatment groups was calculated using two-way ANOVA.Results: Rigvir® (10%, volume/volume) reduced cell viability in FM-9, RD, AGS, A549, HDFa, HPAF-II and MSC cell lines by 67-100%.HaCaT cell viability was partly affected while Rigvir® had no effect on MCF7, Sk-Mel-28 and PBMC viability.Detection of ECHO-7 by immunocytochemistry in FM-9, RD, AGS, A549, HDFa, HPAF-II and Sk-Mel-28 cell lines suggests that the presence of Rigvir® in the cells preceded or coincided with the time of reduction of cell viability.Rigvir® (10%) had no effect on live PBMC count.

Conclusions:The results suggest that Rigvir® in vitro reduces the viability of cells of human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma, pancreas adenocarcinoma but not in PBMC.The presence of Rigvir® in the sensitive cells was confirmed using anti-ECHO-7 antibodies.The present results suggest that a mechanism of action for the clinical benefit of Rigvir® is its cytolytic properties.The present results suggest that the effect of Rigvir® could be tested in other cancers besides melanoma.Further studies of possible Rigvir® entry receptors are needed.

Open the resolved locator · 10.7150/jca.23242

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:47 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v09p1033.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.